In 1993, bevacizumab (BEV) was synthesized for the first time.19 As an anti‐angiogenic monoclonal antibody, BEV can slow the growth of new blood vessels in tumours by inhibiting VEGF‐A.20 As discussed above, two phase III trials combining BEV with radiotherapy and chemotherapy displayed no OS benefit.17 Molecular markers that can predict the effect of BEV on GBM therapy are urgently needed. The gene discussed is VEGFA; the disease is neoplasm.